Stubomycin Was Isolated from the Culture Broth and Mycelia of Streptomyces Strain No. KG-2245 by UMEZAWA Et Al. in 1981.1) Stubo

Total Page:16

File Type:pdf, Size:1020Kb

Stubomycin Was Isolated from the Culture Broth and Mycelia of Streptomyces Strain No. KG-2245 by UMEZAWA Et Al. in 1981.1) Stubo VOL. XXXVI NO. 3 THE JOURNAL OF ANTIBIOTICS 301 STUDIES ON THE BIOLOGICAL ACTIVITY OF STUBOMYCIN KANKI KOMIYAMA,KEN-ICHi EDANAMI, AKIRA TANOH, HIROSHI YAMAMOTOand IWAO UMEZAWA The Kitasato Institute, Minato-ku, Tokyo 108, Japan (Received for publication November 30, 1982) Stubomycin showed direct cytotoxic activity on mammalian cells, yeast, and fungi, and rapid hemolytic activity on mouse erythrocytes. The rate and extent of the cytotoxic and hemolytic activities decreased at lower temperatures. Studies with radioactive precursors revealed that a marginal cytocidal concentration of the antibiotic inhibited synthesis of DNA, RNA, and protein of leukemic cells at almost the same rate. Stubomycin did not show any mutagenicity on mammalian cells and bacteria i.e. the induction of revertants on six bacterial strains, and chromosomal aberrations, sister chromatid exchanges, and the induction of cells resistant to 6-thioguanine on Chinese hamster cells (DON D-6). The antagonistic effect of various kinds of lipids including phospholipids, cholesterol, olive oil and squalene was studied. Significant antagonism of stubomycin against anti-Saccharomyces cerevisiae activity was observed with phospholipids except for egg lecithin and with cholesterol. The primary action of the antibiotic seems to be to change the cell surface and ultimately the lysis and death of the cells. Stubomycin was isolated from the culture broth and mycelia of Streptomyces strain No. KG-2245 by UMEZAWAet al. in 1981.1) Stubomycin has been shown to have marked in vivo antitumor activity on Ehrlich ascites carcinoma, P 388 leukemia, Meth A fibrosarcoma, etc. The antibiotic is also active against Gram-positive bacteria, some fungi, and HeLa cells in vitro.') Recently, OMURAet al. have eluci- dated the structure of stubomycin as a macrocyclic lactam involving (3-phenylalanine.3) This report describes preliminary studies on the cytocidal activity of stubomycin mainly using mammalian cells, yeast, and fungi. Materials and Methods Chemicals N-Ethyl-N'-nitro-N-nitrosoguanidine (ENNG, Nakarai Chemicals Ltd., Kyoto), 2-nitrofluorene .(Aldrich Chemical Co ., USA), and 9-aminoacridine (Tokyo Kasei Kogyo Co., Tokyo) were dissolved in dimethyl sulfoxide. Ethyl methanesulfone and 6-thioguanine (EMS and 6-TG, Sigma Chemical, USA), mitomycin C (Kyowa Hakko Kogyo Co., Tokyo), and benzylpenicillin (Toyo Jozo Co., Shizuoka) were dissolved in phosphate buffer or water. [3H]Thymidine ([3H]TdR, 16.2 Ci/mmole), [3H]uridine ([3H]UR, 38.3 Ci/mmole), and [3H]leucine (158.0 Ci/mmole) were obtained from the Radiochemical Center, Amersham, UK. Cardiolipin, pho- sphatidylserine, and egg lecithin (Kitasato Institute, Tokyo), olive oil and cholesterol (Wako Pure Chemi- cal Industries, Ltd., Osaka), and squalene (Kuraray Co., Osaka) were dissolved in ether or methanol. Cells and Media Salmonella typhimurium strain numbers TA98, 100, 1535, 1537, and 1538, and Escherichia coli WP 2uvrA were provided by Dr. T. KADA,National Institute of Genetics. DON D-6 cells, derived from Chinese hamster lung cells, were maintained in EAGLE'Sminimum essential medium (MEM) supple- mented with fetal calf serum (10 %), sodium pyruvate (1 MM), L-serine (0.2 mm), penicillin (100 u/mI), and streptomycin (100,ag/ml) at 37°C in an atmosphere of 5 % CO, in air. Mouse leukemic EL-4 cells 302 THE JOURNAL OF ANTIBIOTICS MAR. 1983 were maintained in MEM supplemented with 10 % calf serum, and cells in the logarithmic growth phase were used for the experiment. Saccharomyces cerevisiae and Pyricularia oryzae have been maintained in our laboratory on potato agar and rice straw agar respectively. To determine the effect of stubomycin on these microorganisms, two media were used: (1) 0.3 % yeast extract, 0.3 % peptone, 3 % glucose, and 0.3 % Trypticase soy broth for S. cerevisiae; and (2) 0.5 % peptone, 0.3 % yeast extract, and 3 % glucose-potato extract solution (200g of potato was boiled in 1 liter of water for 30 minutes, and the solution was used as potato extract) for P. oryzae. Measurement of Cytotoxicity To determine the cytotoxicity of stubomycin on mammalian cells, EL-4 cells (2 x 106) in 2 ml of medium were placed in 30-mm Petri dishes and incubated for 48 hours. Then, 0.01 ml of different con- centrations of stubomycin solution were added to each culture dish, and thereafter, the number of trypan blue excluded cells was counted periodically using a hemocytometer. In case of antibacterial activity, the antibiotic was added to suspensions of S. cerevisiae (optical density: 0.092) and P. oryzae (optical density: 0.043) in 4 ml of medium, and the mixtures were shaken at 27°C. The growth of S. cerevisiae was followed by determining the absorbancy of cultures at 660 nm. In case of P. oryzae, the culture was gently dispersed by a homogenizer (Biotron), and the growth of P. oryzae was followed by determining the absorbancy of cultures at 660 nm. Values are the mean of three samples. Measurement of Viability EL-4 cells (7 x 105) in 7 ml of MEM were exposed to 0.05 ml of different concentrations of stubo- mycin solution for 5 to 60 minutes. Then at the end of each incubation time, cells were rinsed three times with fresh MEM, and were suspended in 6 ml of culture media. Two ml of each cell suspension were plated on 30-mm Petri dishes. Viable cells were counted after incubation at 37°C for 72 hours. For viable count determination on S. cerevisiae, the microorganism suspended in medium was exposed to different concentrations of stubomycin for 10, 30, or 60 minutes. After incubation, the cells were washed three times with 5 ml of ice-cold medium by centrifugation, diluted with the medium, and plated on potato dextrose agar. After 48 hours of incubation at 37°C, the colonies were counted. Effect of Temperature on Anti-S. cerevisiae Activity of Stubomycin S. cerevisiae (optical density: 0.24) was exposed to 1.25 ,ug/ml of stubomycin for 30 minutes at dif- ferent temperatures. At the end of incubation, the cells were centrifuged at 0°C (600 x g, 2 minutes). The cells were then resuspended in the growth medium. After incubation for 6.5 hours at 27°C, the absorbancy of the cultures was determined at 660 nm. Measurement of Macromolecular Synthesis EL-4 cells (1 X 106 in 2 ml of MEM) were mixed with stubomycin and various precursors, and incu- bated at 37°C for 60 minutes. The cells were then collected on a Millipore filter and rinsed 3 times with ice-cold 5 % trichloroacetic acid. The radioactivity of acid-precipitable material on the filter was deter- mined by a Packard Tri-Carb liquid scintillation spectrometer. Mutagenicity of Stubomycin Effect of Stubomycin on Induction of Revertants in Six Bacterial Strains: The method for detec- tion of mutagenicity as described by AMESet al.') and YAHAGiet al.5>was used. Briefly, stubomycin was dissolved in DMSO and diluted with sterilized distilled water. The antibiotic solution (0.1 ml) was mix- ed with or without 0.5 ml of S-9 solution, and these mixtures were combined with 0.1 ml of bacterial suspension (1 x 109), then incubated at 37°C for 20 minutes. After incubation, 2 ml of soft agar were added to the mixture and the mixture was plated on 90-mm Petri dishes. After 2 days of incubation at 37°C, the number of revertant colonies were counted. As positive mutagen controls, 2-aminoanthracene for the metabolic study and ENNG, 2-nitrofluorene, and 9-aminoanthracene for the non-metabolic study were used according to the bacteria applied as test organism. DNA Damaging Effect of Stubomycin Determined by the rec-Assay: The rec-assay with Bacillus subtilis was performed by the method described by KADAet al.°'7> Briefly, strains of M 45 or H 17 were VOL. XXXVI NO. 3 THE JOURNAL OF ANTIBIOTICS 303 cultured overnight in brain heart infusion broth. Each culture was streaked radially on the surface of broth agar, and a paper disk (diameter: 8 mm) containing the drug test solution was placed over the starting point of the streaks. The plates were kept at 4°C for 30 minutes, then incubated overnight at 37°C. The lengths of the inhibitory zones were measured. Effect of Stubomycin on Chromosomal Aberrations and Sister-chromatid Exchanges in DON Cells : DON cells (1 x 101) in 5 ml of medium were plated on 60-mm Petri dishes and incubated at 37°C for 15 hours. After plating, the cells were exposed to stubomycin or EMS for 31 - 50 hours in medium with or without 5'-bromodeoxyuridine (10-1 M). Three hours prior to harvest, Colcemide was added to give a final concentration in the culture of 0.05 µg/ml. At the time of harvest, the trypsinized cells were gently centrifuged, resuspended in hypotonic saline (0.075 M KCI) and allowed to stand for 10 minutes. After fixation with a mixture of methanol - acetic acid (3: 1), the cell suspensions were dropped onto slides, allowed to air dry and stained with Giemsa. Effect of Stubomycin on Induction of Mutation Resistant to 6-TG in DON Cells: DON cells (2 x 101) in 4.5 ml of medium were plated in 25-cm' plastic flasks (Corning, USA). After plating, 0.5 ml of the antibiotic or EMS solution was added to the culture which was then reincubated for 15.5 hours. The resulting culture was washed with phosphate buffered saline, resuspended in fresh MEM, and further incubated for 8.5 hours (day 0). To express mutation, the cells were subcultivated every other day, and the cells were trypsinized to select the mutants on days 13 or 15. The resulting cells (5 x 104) in 10 ml of medium containing 6-TG (10-1 M) were plated on 100-mm Petri dishes.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,879,798 B1 Aufseeser (45) Date of Patent: Feb
    US007879798B1 (12) United States Patent (10) Patent No.: US 7,879,798 B1 Aufseeser (45) Date of Patent: Feb. 1, 2011 (54) COMPOSITION FOR INDOLENT WOUND Mazzotta, M.Y. “Nutrition and Wound Healing.” J. Am. Podiatr. Med. HEALING AND METHODS OF USE Assoc. 84(9): 456-462, Sep. 1994. THEREFOR Niedermeier, S. "Tierexperimentelle Untersuchungen Zur Frage der Behandlung von Hornhautlasionen Animal experiment studies on the problem of treating corneal lesions.” Klin. Monatsbl. (75) Inventor: Leslie S. Aufseeser, Lakewood, NJ (US) Augenheilkd (Germany, West), 190 (1):28-9, Jan. 1987. Seifter, E. etal. “Impaired Wound Healing in Streptozotocin diabetes. (73) Assignee: Regenicel, Inc., Lakewood, NJ (US) Prevention by supplemental Vitamin A.” Ann. Surgery (US). 194(1): 42-50, Jul. 1981. (*) Notice: Subject to any disclaimer, the term of this Gilmore, O.J.A. etal. “Aetiology and prevention of wound infection patent is extended or adjusted under 35 in appendicetomy.” British Journal of Surgery, 61:281-287. Mar. U.S.C. 154(b) by 594 days. 1974. Lowenfels, Albert B. “Viewpoints: Wound Healing With No Oint (21) Appl. No.: 11/895,474 ment, Non-antibiotic Ointment, or Antibiotic Ointment”. Medscape General Surgery. 8(2), 2006. (22) Filed: Aug. 24, 2007 United States Food and Drug Administration. “First Aid Antibiotic Drug Products”. Code of Federal Regulations, Title 21, vol. 5, Chap (51) Int. Cl. ter I, Part 333, Subpart B, pp. 222-225, Apr. 1, 2006. A6 IK 38/12 (2006.01) Akpek, EK et al. "A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis.” (52) U.S.
    [Show full text]
  • From Sugar Based Bio Renewable Resources to New Chemical Building Blocks and Bioactive Molecules
    Raquel Alexandra Germano Nunes Licenciatura em Química Aplicada From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Co-orientador: Rafael Filipe Teixeira Arbuéz Gomes, MSc, FF-UL Presidente: Prof. Doutora Paula Cristina de Sério Branco, FCT-UNL Arguente: Prof. Doutora Luísa Maria da Silva Pinto Ferreira, FCT-UNL Vogal: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Março 2017 LOMBADA Raquel Nunes Raquel From sugar based bio renewable resources to new chemical building blocks and bioactive molecules bioactive and blocks chemical new building to resources renewable bio based sugar From 2017 Raquel Alexandra Germano Nunes Licenciatura em Química Aplicada From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Co-orientador: Rafael Filipe Teixeira Arbuéz Gomes, MSc, FF-UL Presidente: Prof. Doutora Paula Cristina de Sério Branco, FCT-UNL Arguente: Prof. Doutora Luísa Maria da Silva Pinto Ferreira, FCT-UNL Vogal: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Março 2017 From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Copyright © Raquel Alexandra Germano Nunes, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa. A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por outro qualquer meio conhecido ou que venha a ser inventado e de divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor.
    [Show full text]
  • Antibiotic Discovery
    ANTIBIOTIC DISCOVERY RESISTANCE PROFILING OF MICROBIAL GENOMES TO REVEAL NOVEL ANTIBIOTIC NATURAL PRODUCTS By CHELSEA WALKER, H. BSc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree Master of Science McMaster University © Copyright by Chelsea Walker, May 2017 McMaster University MASTER OF SCIENCE (2017) Hamilton, Ontario (Biochemistry and Biomedical Sciences) TITLE: Resistance Profiling of Microbial Genomes to Reveal Novel Antibiotic Natural Products. AUTHOR: Chelsea Walker, H. BSc. (McMaster University) SUPERVISOR: Dr. Nathan A. Magarvey. COMMITTEE MEMBERS: Dr. Eric Brown and Dr. Michael G. Surette. NUMBER OF PAGES: xvii, 168 ii Lay Abstract It would be hard to imagine a world where we could no longer use the antibiotics we are routinely being prescribed for common bacterial infections. Currently, we are in an era where this thought could become a reality. Although we have been able to discover antibiotics in the past from soil dwelling microbes, this approach to discovery is being constantly challenged. At the same time, the bacteria are getting smarter in their ways to evade antibiotics, in the form of resistance, or self-protection mechanisms. As such is it essential to devise methods which can predict the potential for resistance to the antibiotics we use early in the discovery and isolation process. By using what we have learned in the past about how bacteria protect themselves for antibiotics, we can to stay one step ahead of them as we continue to search for new sources of antibiotics from bacteria. iii Abstract Microbial natural products have been an invaluable resource for providing clinically relevant therapeutics for almost a century, including most of the commonly used antibiotics that are still in medical use today.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Session Abstracts In
    Natural Product Discovery and Development in the Genomic Era Sunday, January 21 12:00 PM - 6:00 PM Registration Grand Ballroom Foyer, lobby level 5:00 PM - 6:00 PM Keynote Speech: Nigel Mouncey, Director Joint Genome Institute "New Voyages to Explore the Natural Product Galaxy" Salons F-G, lobby level 6:00 PM - 7:00 PM Welcome Reception Salons A-E, lobby level 6:00 PM - 8:00 PM Session: PS1: Poster Session 1 Salons A-E, lobby level P1 Sonogashira diversification of unprotected halotryptophans, halotryptohan containing tripeptides; and generation of a new to nature bromo-natural product and its diversification in water C. Cartmell*, University of St. Andrews, Strathkinness, United Kingdom The blending together of synthetic chemistry and natural product biosynthesis provides a potentially powerful route to new natural product analogues2. Cystargamide is a structurally interesting lipo-depsi peptide containing a 5-hydroxy tryptophan as well as a 2, 3-epoxydecanoyl fatty acid chain3. We envisaged that by installing a sufficiently reactive handle (e.g. a C-Br bond) and developing compatible mild aqueous chemistries, biosynthesis of the halo-cystargamides and its subsequent chemical modification can be achieved. Precursor directed biosynthesis (PDB) provides a great potential for the production of new natural product analogues by exploiting the natural promiscuity of the enzymes involved in the biosynthesis of natural product. Using PDB method, we achieved the incorporation of various chloro/bromo-tryptophans and generated a series of halogenated analogues of cystargamide. 6- Br-cystargamide was subsequently diversified using aqueous cross coupling chemistries such as the Sonogashira reaction to obtain new derivatives of cystargamide.
    [Show full text]
  • Microbial Lactam Biosynthesis and Biosensing by Jingwei Zhang a Dissertation Submitted in Partial Satisfaction of the Requiremen
    Microbial Lactam Biosynthesis and Biosensing by Jingwei Zhang A dissertation submitted in partial satisfaction of the requirements for the degree of Joint Doctor of Philosophy with University of California, San Francisco in Bioengineering in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Jay Keasling, Chair Professor John Dueber Professor Shawn Douglas Professor Wenjun Zhang Fall 2015 Microbial Lactam Biosynthesis and Biosensing Copyright 2015 by Jingwei Zhang Abstract Microbial Lactam Biosynthesis and Biosensing by Jingwei Zhang Joint Doctor of Philosophy with University of California, San Francisco in Bioengineering University of California, Berkeley Professor Jay D. Keasling, Chair Lactam is an important class of commodity chemicals used in the manufacture of nylons, with millions of tons of production every year. 2-Pyrrolidone is a valuable bulk chemical with myriad applications as a solvent, polymer precursor and active pharmaceutical intermediate. A novel 2-pyrrolidone synthase, ORF27, from Streptomyces aizunensis was identified to catalyze the ring closing dehydration of γ- aminobutyrate. ORF27’s tendency to aggregate was resolved by expression at low temperature and fusion to the maltose binding protein (MBP). Recombinant Escherichia coli was metabolically engineered for the production of 2-pyrrolidone from glutamate by expressing both the genes encoding GadB, a glutamate decarboxylase, and ORF27. Incorporation of a GadB mutant lacking H465 and T466, GadB_ΔHT, improved the efficiency of one-pot 2-pyrrolidone biosynthesis in vivo. When the recombinant E. coli strain expressing the E. coli GadB_ΔHT mutant and the ORF27-MBP fusion was cultured in ZYM-5052 medium containing 9 g/L of L- glutamate, 7.7 g/L of L-glutamate was converted to 1.1 g/L of 2-pyrrolidone within 31 h, achieving 25% molar yield from the consumed substrate.
    [Show full text]
  • Substance Index for Volume 66
    The Journal of Antibiotics (2013) 66, 749–753 & 2013 Japan Antibiotics Research Association All rights reserved 0021-8820/13 www.nature.com/ja Substance Index for Volume 66 (3R,4R)-4-Acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy) 161 A26771B 123 ethyl]-2-azetidinone AB3217-A 123 4-O-(400-O-Acetyl-a-L-rhamnopyranosyl)-ellagic acid 123 Acidomycin 371 Bedaquiline 571 Aclacinomycin A, N-benzyl- 165 4-O-Benzoyl-2,3,6-trideoxy-3-C-methyl-3- 131 Actinopyrone A 123 trifluoroacetamido-a,b-L-lyxo-hexopyranosyl acetate Actinorhodin 387 4-O-Benzyl-2,3,6-trideoxy-3-C-methyl-3-azido-a,b-L-lyxo- 131 Actinorhodin, diepoxy 295 hexopyranosyl acetate AFN-1252 571 4-O-Benzyl-2,3,6-trideoxy-3-C-methyl-3- 131 Albaflavenone 387 trifluoroacetamido-a,b-L-lyxo-hexopyranosyl acetate Albocycline 303 (S, Z)-3-Benzylidene-6-isopropylpiperazine-2,5-dione 31 Allosamizoline 123 (S, Z)-3-Benzylidene-6-methylpiperazine-2,5-dione 31 N-Allyl-aclacinomycin A 165 3-Benzylpiperazine-6-(4-methoxybenzylidene)-2,5-dione 31 (4R*,6R*,8S*)-8-Allyl-9,9-dimethyl-1-methoxy-4- 141 Bhimamycin F, H, I 719 prenyl-6-((triisopropylsilyloxy)methyl)bicyclo Biapenem 571 [3.3.1]non-1-ene-3,5-dione Biemodin 491 (4S*,6R*,8S*)-3-(8-Allyl-9,9-dimethyl-1-methoxy-6- 141 Brartemicin analogs 531 ((triisopropylsilyloxy)methyl)bicyclo[3.3.1]non-1- Brilacidin 571 ene-3,5-dione-4-yl)methyl)-2,2-dimethyloxirane (3S)-4-Bromo-2,3-dimethylbut-1-ene 147 (4S*,6R*,8S*,18S*)-8-Allyl-18-(1-hydroxy-1-methylethyl) 141 (2E,5R)-1-tert-Butyldiphenylsilyloxy-5- 155 -9,9-dimethyl-6-((triisopropylsilyloxy)methyl)-31- methanesulfonyloxy-2-methylhex-2-ene
    [Show full text]
  • Taxonomic Characterization and Secondary Metabolite Analysis of NEAU-Wh3-1: an Embleya Strain with Antitumor and Antibacterial Activity
    microorganisms Article Taxonomic Characterization and Secondary Metabolite Analysis of NEAU-wh3-1: An Embleya Strain with Antitumor and Antibacterial Activity 1, 1, 1 1 1 1 1,2, Han Wang y, Tianyu Sun y, Wenshuai Song , Xiaowei Guo , Peng Cao , Xi Xu , Yue Shen * and Junwei Zhao 1,* 1 Key Laboratory of Agricultural Microbiology of Heilongjiang Province, Northeast Agricultural University, No. 600 Changjiang Road, Xiangfang District, Harbin 150030, China; [email protected] (H.W.); [email protected] (T.S.); [email protected] (W.S.); [email protected] (X.G.); [email protected] (P.C.); [email protected] (X.X.) 2 College of Science, Northeast Agricultural University, No. 600 Changjiang Road, Xiangfang District, Harbin 150030, China * Correspondence: [email protected] (Y.S.); [email protected] (J.Z.) These authors contributed equally to this work. y Received: 28 February 2020; Accepted: 18 March 2020; Published: 20 March 2020 Abstract: Cancer is a serious threat to human health. With the increasing resistance to known drugs, it is still urgent to find new drugs or pro-drugs with anti-tumor effects. Natural products produced by microorganisms have played an important role in the history of drug discovery, particularly in the anticancer and anti-infective areas. The plant rhizosphere ecosystem is a rich resource for the discovery of actinomycetes with potential applications in pharmaceutical science, especially Streptomyces. We screened Streptomyces-like strains from the rhizosphere soil of wheat (Triticum aestivum L.) in Hebei province, China, and thirty-nine strains were obtained. Among them, the extracts of 14 isolates inhibited the growth of colon tumor cell line HCT-116.
    [Show full text]
  • Metabolomics and Chemical Library Screening for Antibacterial
    METABOLOMICS AND CHEMICAL LIBRARY SCREENING FOR ANTIBACTERIAL DRUG DISCOVERY A DISSERTATION IN Pharmaceutical Sciences and Chemistry Presented to the Faculty of University of Missouri-Kansas City in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY By NAVID JUBAER AYON MS, University of Missouri-Kansas City, 2019 MPharm, University of Dhaka, 2013 BPharm, University of Dhaka, 2012 Kansas City, Missouri, USA 2020 © 2020 NAVID JUBAER AYON ALL RIGHTS RESERVED ii METABOLOMICS AND CHEMICAL LIBRARY SCREENING FOR ANTIBACTERIAL DRUG DISCOVERY Navid Jubaer Ayon, Candidate for the Doctor of Philosophy Degree University of Missouri–Kansas City, 2020 ABSTRACT There are twenty standard amino acids which are proteinogenic and can exist in two stereoisomeric forms, D- and L-enantiomers, except for glycine, which is achiral. The D-amino acids are not incorporated in proteins; however, they play important roles in many biological systems and processes. Amino acids are polar analytes and are difficult to separate on traditional silica based stationary phases in reverse phase chromatography to allow accurate quantification in their natural form. In part I of this dissertation, we investigated the use of a chiral derivatizing reagent known as Marfey’s reagent, coupled with liquid chromatography tandem mass spectrometry (LC-MS/MS) based separation and quantification for the common proteinogenic amino acid D- and L- stereoisomers. We compared standard formic acid and ammonium acetate based solvent systems in both positive and negative modes; and established baseline separation with superior sensitivity for all nineteen amino acid pairs and glycine with an analytical C8 column in reverse phase chromatography in negative ionization mode using an ammonium acetate based neutral solvent system.
    [Show full text]
  • WO 2015/017866 Al 5 February 2015 (05.02.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/017866 Al 5 February 2015 (05.02.2015) P O P C T (51) International Patent Classification: Gregory, B. [US/US]; C/o 83 Cambridge Parkway, Cam C12N 15/63 (2006.01) C40B 40/06 (2006.01) bridge, MA 02142 (US). C12N 15/87 (2006.01) (74) Agents: ALTIERI, Stephen, L. et al; Bingham Mc- (21) International Application Number: cutchen LLP, 2020 K Street, NW, Washington, DC 20006- PCT/US20 14/049649 1806 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 4 August 2014 (04.08.2014) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/861,805 2 August 2013 (02.08.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/883,13 1 26 September 2013 (26.09.2013) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 61/935,265 3 February 2014 (03.02.2014) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 61/938,933 12 February 2014 (12.02.2014) US TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant: ENEVOLV, INC.
    [Show full text]
  • Book of Abstracts
    4th Annual Russian-Korean Conference “Current Issues of Natural Products Chemistry and Biotechnology” September, 18-21, 2012, Novosibirsk, Russia Table of Contents Biologically Active Extractives of Larch as the Basis for New Medicines Babkin V.A. ................................................................................................................................... 10 New Rearrangements in the Semiaminal Series Kartsev V.G., Zubenko A.A. ......................................................................................................... 11 Macrocycles Constructed from One or More Molecules of Diterpenoid Isosteviol Isolated from the Glycosides of Stevia rebaudiana Kataev V.E., Strobykina I.Yu., Andreeva O.V., Garifullin B.F. and Khaybullin R.N. ................ 13 Steroid Phytohormones: New Directions in Studies and Applications Khripach V.A., Zhabinskii V.N. ................................................................................................... 14 Sesquiterpene Lactones in Medicinal Chemistry Klochkov S.G. ............................................................................................................................... 15 Catalytic Transformations of Wood Derived Lignans Murzin D.Yu. ................................................................................................................................ 16 Chemical Transformations and Biological Activities of Anthraquinones Muzychkina R.A., Korulkin D.Yu. ..............................................................................................
    [Show full text]
  • Protecting Groups Third Edition by Philip J. Kocieński
    Protecting Groups Third Edition by Philip J. Kocieński Protecting Groups Third Edition by Philip J. Kocieński Index acetal exchange 126, 136, 154, 160, 293, N-adenylated S-methyl-l-cysteine sulfox- 316, 566 imine 516 acetalisation 59–60, 64 Agelastatin A 508, 555 N,N-acetals 98, 369–371, 388 Agrocin 84 477 N,O-acetals 96–99, 173–179, 232, AI-77-B 576 561–568, 626–630 alanine 552 O,O-acetals 5–7, 11, 50–77, 101, 120–160, Albomycin 595 285–320, 342, 426–430 aldol reaction, directed 26 acetamidomethyl 372, 381, 384 alkene 516 acetate esters 3, 168, 206, 325, 334, 338 alkenes, terminal 55 acetate migration 196, 336 O-alkyl nucleophilic scission 399 80% acetic acid 595 alkylammonium formate 467 acetic acid 5–6, 139–140, 156, 175–176, alkylation 39, 87, 94, 370 190, 196, 200, 208, 216, 265, 269, 315, alkylation, asymmetric 411 318, 341, 343, 461, 529, 564–565, 582 S-alkylation 7 acetic acid in ether 599 alkyllithium reagents 137 acetic acid in refluxing 2-propanol 404 allene 70 acetic anhydride 156, 238, 298, 323, 497, Allopumiliotoxin 339A 245 559 Allosamidin 557 acetonides 202 allyl alcohol 606 a-acetoxy 92 allyl bromide 595 p-acetoxybenzyloxycarbonyl (AcOZ) group allyl carbamate 39 518 allyl chloroformate 284, 346, 423, 528 acetoxymethyl acetal 156 allyl esters 12, 37, 422, 517, 526 acetoxymethyl ether 157 allyl ethers 12–13, 39, 246, 276, 278, 422 2-(acetoxymethyl)benzamides 501 allyl isopropenyl dicarbonate 423 N-acetyl neuraminic acid 4, 177, 258, 330 p-allyl palladium 12, 418, 422, 594–595, 2-acetyldimedone 606 606–607 acetylene 490
    [Show full text]